SCHEMBL24547754

SCHEMBL24547754

Cn1ncc2c1c1ccccc1n2C(=O)C12C3C4C5C3C1C5C42

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.42
LMNA P02545 4/20 0.42
HSD17B10 Q99714 4/20 0.42
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 3/20 0.42
GLA P06280 2/20 0.42
GAA P10253 2/20 0.42
POLB P06746 1/20 0.39
HTT P42858 3/20 0.37
MAPK1 P28482 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
ATM Q13315 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24547751 0.78 SMN1; SMN2 (0.47) HPGDLMNAHSD17B10KDM4EALDH1A1
SCHEMBL24547744 0.77 KDM4E (0.45) HPGDLMNAHSD17B10KDM4EALDH1A1
SCHEMBL24547742 0.75 P2RX4 (0.56) HPGDLMNAHSD17B10KDM4EALDH1A1
SCHEMBL24547765 0.74 KDM4E (0.45) HPGDLMNAHSD17B10KDM4EALDH1A1
SCHEMBL24547758 0.74 ELANE (0.46) HPGDLMNAHSD17B10KDM4EALDH1A1
SCHEMBL24547777 0.74 IDH1 (0.37) HPGDLMNAHSD17B10KDM4EALDH1A1
SCHEMBL24547759 0.73 HTR7 (0.53) HTR7
SCHEMBL24547660 0.73 ELANE (0.45) HPGDLMNAHSD17B10KDM4EALDH1A1
SCHEMBL24547757 0.73 ELANE (0.45) HPGDLMNAHSD17B10KDM4EALDH1A1
SCHEMBL24547630 0.72 LMNA (0.48) HPGDLMNAHSD17B10KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067654-A1 OXYTOCIN RECEPTOR MODULATORS Kinoxis Therapeutics Pty Ltd (AU) 2024-02-29 US disclosed
US-20240067654-A1 OXYTOCIN RECEPTOR MODULATORS Kinoxis Therapeutics Pty Ltd (AU) 2024-02-29 US disclosed
WO-2022126179-A1 OXYTOCIN RECEPTOR MODULATORS THE UNIVERSITY OF SYDNEY (AU) 2022-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067654-A1 OXYTOCIN RECEPTOR MODULATORS OXTR, AVPR1B, AVPR1A HPGD 564/4885LMNA 2876/4885HSD17B10 2045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.